Golden Lab sold eye and allergy capsules with unapproved drug claims and lacked required supplement manufacturing controls.
What happened
FDA inspected Golden Lab's Jacksonville, Florida facility on November 1, 2, 3 and 10, 2021, and reviewed labels collected during the inspection and the website www.doctorsoptimalformula.com. FDA found claims that the products were intended to treat glaucoma, ocular hypertension, macular degeneration, and ocular allergies, making them unapproved new drugs, and found current Good Manufacturing Practice (cGMP) violations for dietary supplements. The investigators' observations were issued on Form FDA-483, Inspectional Observations, on November 10, 2021, and amended on November 16, 2021.
What FDA found
Product labels and the website claimed the capsules treat glaucoma, ocular hypertension, macular degeneration, and ocular allergies, so FDA treats them as unapproved new drugs needing FDA approval.
21 U.S.C. § 321(g)(1)(B), 321(p); 21 U.S.C. §§ 331(d), 355(a)Two DoctoRx eye products were misbranded (improperly labeled) because they were for diseases not suitable for self-treatment and lacked adequate directions for lay use.
21 U.S.C. § 352(f)(1); 21 CFR 201.5Golden Lab had no finished-product specifications for identity, purity, strength, composition, or contaminant limits for several supplement products.
21 CFR 111.70(e)Golden Lab failed to establish component specifications for listed ingredients and did not show required identity testing and specification records.
21 CFR 111.70(b)(2), 111.73, 111.75(a)(1)(i), 111.75(a)(2), 111.75(c), 111.95Batch production records for several products lacked quality-control release documentation and documentation of manufacturing steps, initials, weights, and component additions.
21 CFR 111.255(b), 111.260(j), 111.260(l)(3)Hourzzz Sublingual Drops were marketed as a dietary supplement, but FDA said sublingual products are not intended for ingestion and so are not dietary supplements.
21 U.S.C. § 321(ff)(2)(A)(i)
What FDA wants
FDA asks Golden Lab to notify it in writing within 15 working days of the specific steps taken to address the violations, with explanations, prevention steps, and related documentation; if corrective actions cannot be completed in that time, the company must state the reason and expected completion time.
Who should pay attention
- brands selling eye-health or allergy supplements
- dietary supplement contract manufacturers
- retailers and distributors of supplement products with disease claims
This is a summary. Read the original letter on fda.gov.